Fukumoto S, Terashita Z, Ashida Y, Terao S, Shiraishi M
Pharmaceutical Research Laboratories II, Takeda Chemical Industries, Ltd., Osaka, Japan.
Chem Pharm Bull (Tokyo). 1996 Apr;44(4):749-55. doi: 10.1248/cpb.44.749.
Enantiomers of four potent nonprostanoid thromboxane A2 (TXA2) receptor antagonists, (+/-)-7-(4-fluorophenyl)-7-(2-hydroxyphenyl)heptanoic acids (1-4), were synthesized stereoselectively by direct ortho-alkylation of phenols under modified Mitsunobu conditions. The reaction of 5 eq of phenols (6a-c) with 1 eq of (S)- or (R)-methyl 7-(4-fluorophenyl)-7-hydroxyheptanoate ((S)- or (R)-7) afforded ortho-alkylated phenol derivatives (6a-c) enantioselectively in 33 to 42% chemical yield and 90 to 93% ee. In these compounds, the (R)-enantiomers (1-4) exhibited potent TXA2 receptor antagonistic activity and the (S)-isomer (3) was much less active. In particular, compound (R)-3 strongly inhibited U-46619-induced human platelet aggregation (IC50 = 48 nM), and also showed a very potent inhibitory effect with a minimum effective dose (MED) of 0.3 mg/kg (p.o.) on U-46619-induced bronchoconstriction in guinea pigs.
通过在改良的 Mitsunobu 条件下对酚进行直接邻位烷基化反应,立体选择性地合成了四种强效非前列腺素血栓素 A2(TXA2)受体拮抗剂(±)-7-(4-氟苯基)-7-(2-羟基苯基)庚酸(1-4)的对映体。5 当量的酚(6a-c)与 1 当量的(S)-或(R)-7-(4-氟苯基)-7-羟基庚酸甲酯((S)-或(R)-7)反应,以 33%至 42%的化学产率和 90%至 93%的对映体过量(ee)对映选择性地得到邻位烷基化的酚衍生物(6a-c)。在这些化合物中,(R)-对映体(1-4)表现出强效的 TXA2 受体拮抗活性,而(S)-异构体(3)的活性则低得多。特别是,化合物(R)-3 强烈抑制 U-46619 诱导的人血小板聚集(IC50 = 48 nM),并且在豚鼠中对 U-46619 诱导的支气管收缩也显示出非常强效的抑制作用,最小有效剂量(MED)为 0.3 mg/kg(口服)。